Phaseline

Targets › EPCAM

EPCAM (Epithelial cell adhesion molecule): drug programs, companies and trials

4 programs from 4 companies in 7 trials: 5 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Immunology, Other; next expected readout Nov 2026.

May act as a physical homophilic interaction molecule between intestinal epithelial cells (IECs) and intraepithelial lymphocytes (IELs) at the mucosal epithelium for providing immunological barrier as a first line of defense against mucosal infection. Plays a role in embryonic stem cells proliferation and differentiation. (UniProt, P16422)

Open in Phaseline: the race on EPCAM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Wuhan YZY BiopharmaM701
anti-EpCAM and anti-CD3 human-mouse chimeric bispecific antibody
EPCAM, CD3EPhase 3Malignant Ascites; Malignant Pleural EffusionsDec 2026
Mirador TherapeuticsAdecatumumab (MT-201)
Epithelial cell adhesion molecule inhibitor
EPCAMPhase 2Inflammatory Bowel Disease (IBD); Healthy VolunteerNov 2026
AcadeMab BiomedicalAM-928
anti-EpCAM monoclonal antibody
EPCAMPhase 1Advanced Solid TumorJun 2027
BioAtlaBA3182
Conditionally active bispecific T-cell engager (BiTE) antibody targeting EpCAM and CD3
EPCAM, CD3EPhase 1Advanced AdenocarcinomaSep 2028

Conditions

Healthy Volunteer (2) Malignant Ascites (1) Malignant Pleural Effusions (1) Advanced Solid Tumor (1) Inflammatory Bowel Disease (IBD) (1) Advanced Adenocarcinoma (1)

Modalities

small molecule (3), protein or peptide (1)

Companies

Wuhan YZY Biopharma (1) AcadeMab Biomedical (1) Mirador Therapeutics (1) BioAtla (1)

Related targets

CD3E (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.